Caribou: 12-month CB-010 data shows durable CR in 2/6; selects ROR1 for CB-020

Caribou Biosciences, Inc.

CB-010 ANTLER cohort 1: 6/6 CR best response; 3/6 durable CR at 6 months; 2/6 maintain CR at 12 months; longest CR 18 months.
FDA granted CB-010 RMAT and Fast Track designations; dose level 2 (80x10^6) no DLTs; enrolling dose level 3 (120x10^6).
Selected ROR1 as target for CB-020 iPSC-derived allogeneic CAR-NK cell therapy; preclinical data shows significant tumor burden reduction in xenograft model.
Armoring strategies for CAR-NK platform: CBLB knockout, B2M knockout with HLA-E insertion, membrane-bound IL-15/IL-15RA fusion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.